Agents Contraindicated With QT Agents/QT Prolonging Agents (mono deleted 09/16/2013)
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both of your medicines may affect your heart's rhythm.
What might happen:
Taking two or more medicines that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g doctor or pharmacist) know right away that you are taking these medications together. Let your doctor know right away if you notice an irregular heartbeat or have dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
2.Vascor (bepridil hydrochloride) US prescribing information. Ortho-McNeil Pharmaceutical, Inc. March, 2000.
3.Multaq (dronedarone) US prescribing information. Sanofi-Aventis U.S. LLC March, 2013.
4.Orlaam (levomethadyl acetate hydrochloride) US prescribing information. Roxane Laboratories, Inc. May, 2001.
5.Orap (pimozide) US prescribing information. Gate Pharmaceuticals August, 2011.
6.Eurartesim (piperaquine tetraphosphate-dihydroartemisinin) UK summary of product characteristics. Sigma-tau Pharma Limited UK October 27. 2011.
7.Serdolect (sertindole) UK summary of product characteristics. Lundbeck Limited October 25, 1996.
8.Zagam (sparfloxacin) US prescribing information. Bertek Pharmaceuticals, Inc. February, 2003.
9.Geodon (ziprasidone hydrochloride) US prescribing information. Pfizer Inc. December, 2010.
10.Propulsid (cisapride) US prescribing information. Janssen Pharmaceutica January, 2000.
11.Inapsine (droperidol) US prescribing information. Akorn, Inc. November, 2001.
12.Halfan (halofantrine hydrochloride) US prescribing information. SmithKline Beecham Pharmaceuticals October, 2001.
13.Cordarone X (amiodarone hydrochloride) Australian prescribing information. Sanofi-Synthelabo Australia Pty Limited Augsut 15, 2007.
14.Cordarone X (amiodarone hydrochloride) UK summary of product characteristics. Sanofi-Aventis July 6, 2010.
15.Cordarone (amiodarone hydrochloride) US prescribing information. Wyeth Pharmaceuticals November, 2011.
16.Riamet (artemether/lumefantrine) UK summary of product characteristics. Novartis Pharmaceuticals UK Ltd. June 27, 2001.
17.Coartem (artemether/lumefantrine) US prescribing information. Novartis Pharmaceuticals Corporation April, 2013.
18.Rythmodan (disopyramide) Australian prescribing information. Aventis Pharma Pty Ltd. September 22, 2000.
19.Tikosyn (dofetilide) US prescribing information. Pfizer Inc. February, 2011.
20.Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) US prescribing information. Avanir Pharmaceuticals August, 2011.
21.Zelboraf (vemurafenib) US Prescribing Information. Hoffman-La Roche July, 2013.
22.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.
23.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.